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The differential effect of Toxoplasma gondii infection on the 
stability of BCL2-family members involves multiple activities
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The regulation of mitochondrial permeability, a key event in the initiation of apoptosis is governed 
by the opposing actions of the pro- and anti-apoptotic members of the BCL2-family of proteins. 
The BCL2-family can be classified further based on the number of BCL-homology (BH) domains 
they encode. Pathogen mediated modulation of BCL2-family members play a significant role 
in their ability to affect the apoptotic pathways in the infected host cell. The protozoan parasite 
Toxoplasma gondii establishes a profound blockade of apoptosis noted by a requirement for 
host NFκB activity and correlating with the selective degradation of pro-apoptotic BCL2-family 
members. In this study, we explore the potential activities associated with the inherent stability 
of the anti-apoptotic BCL2 as well as the selective degradation of the pro-apoptotic proteins 
BAX, BAD, and BID. We find that multiple activities govern the relative stability of BCL2-family 
members suggesting a complex and balanced network of stability-enhancing and–destabilizing 
activities are perturbed by parasite infection. The data leave open the possibility for both parasite 
induced host activities as well as the direct consequence of parasite effectors in governing the 
relative levels of BCL2-proteins in the course of infection.
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Much of this control is mediated by the opposing actions of the 
anti-apoptotic and pro-apoptotic members of the BCL2-family of 
proteins (Scorrano and Korsmeyer, 2003; Brunelle and Letai, 2009). 
These proteins are classified based on their activity and the number 
of BCL2-homology (BH) domains (reviewed in Thomadaki and 
Scorilas, 2008; Brunelle and Letai, 2009). Accordingly the anti-
 apoptotic BCL2 contains four BH domains (BH1, 2, 3, 4; Liston 
et al., 2003). Among the pro-apoptotic members are the multi-
domain protein (BAX, containing BH1, 2, 3; Lalier et al., 2007) 
and the BH3 only proteins BAD and BID (Marsden and Strasser, 
2003). The anti-apoptotic BCL2 actively interferes with permeabili-
zation of the mitochondrial outer membrane (MOM) by the multi-
domain proteins (e.g., BAX) thus blocking apoptosis (Thomadaki 
and Scorilas, 2008; Brunelle and Letai, 2009). Displacement of the 
protective BCL2 from BAX is mediated by members of the BH3 only 
sub-family thus promoting apoptosis (Thomadaki and Scorilas, 
2008; Brunelle and Letai, 2009). Although controversial, BH3 only 
proteins may exert their effect additionally by the direct activation 
of BAX (Wu and Deng, 2002). Regardless of the mechanism of 
action, BH3 only proteins shift the balance toward a pro-apoptotic 
state. This stringent and nuanced level of control over the release 
of cytochrome c is susceptible to pathogen manipulation.
Manipulation of the BCL2-family has been observed for viral 
(Galluzzi et al., 2008), bacterial (Faherty and Maurelli, 2008), and 
protozoan pathogens (Carmen and Sinai, 2007). The consequence 
of this manipulation is to either promote or inhibit apoptosis, 
 resulting in an outcome that is advantageous to the specific patho-
gen. Our earlier work demonstrated that infection of mammalian 
IntroductIon
The protozoan parasite Toxoplasma gondii is an important oppor-
tunistic infection in immune compromised individuals and a sig-
nificant cause of birth defects when congenitally acquired (Tenter 
et al., 2000). As an obligate intracellular pathogen, T. gondii has 
successfully adapted to the intracellular environment (Boyle 
and Radke, 2009). In doing so the parasite has evolved complex 
mechanisms to interfere with or neutralize normal host defenses 
(Boothroyd, 2009). Among these is the apoptotic cascade which we 
and others have shown is profoundly inhibited in parasite infected 
cells (reviewed in Carmen and Sinai, 2007). The inhibition of apop-
tosis is connected with the ability of T. gondii to manipulate the 
NFκB pathway evidenced by the fact that the blockade of apoptosis 
is lifted in NFκB (RelA/p65−/−) knock out cells (Payne et al., 2003). 
While critically important, not all the anti-apoptotic events sur-
rounding the blockade are channeled through NFκB as we recently 
demonstrated with regard to the parasite mediated inhibition of 
JNK activation in HeLa cells (Carmen et al., 2008).
The role of mitochondria in the activation of apoptosis is well 
documented (Pinkoski et al., 2006; Wang and Youle, 2009). The key 
triggering event committing a cell to apoptosis is the release of cyto-
chrome c from the mitochondria inter-membrane space (Goldstein 
et al., 2000; Gogvadze et al., 2006) resulting in the formation of the 
apoptosome (Zou et al., 1999). The recruitment and activation of 
the caspases in the apoptosome initiates the systematic dismantling 
of the cell due to targeted degradation of critical caspase substrates 
(Abu-Qare and Abou-Donia, 2001; Baliga and Kumar, 2003). The 
release of cytochrome c is therefore under tight regulatory control. 
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anti-BID (1:4000, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 
sc-11423). Blots were stripped and reprobed with an anti-calnexin 
antibody to verify equal protein loading as previously described 
(Carmen et al., 2008). Detection of reactive proteins was achieved 
using enhanced chemiluminescence (Pierce) recorded on X-ray 
film (Fuji) as previously described (Carmen et al., 2006).
InhIbItIon of the proteasome and specIfIc protease classes
Proteasome/protease inhibitor studies were performed using the 
following experimental design. Cells were seeded into six-well 
dishes and, after an 8-h incubation period, infected at the MOI 
described in the figure. Uninfected and infected cells were incubated 
with the various inhibitors for the last 8 h of a 24-h infection period. 
At the end of inhibitor treatment, cells were harvested and analyzed 
using SDS-PAGE and immunoblotting. The role of the protea-
some in T. gondii-dependent BCL2-family member degradation 
was determined by analyzing the levels of BCL2, BAX, BAD, and 
BID in cells treated with 20 μM MG132. The MG132 stock solution 
was made in DMSO and an equal volume of the carrier was added to 
the untreated samples. The protease inhibitors E64d, leupeptin, and 
Nα-tosyl-phenylalanyl chloromethyl ketone (TPCK) were used to 
experimentally determine the role of cysteine proteases (E64d) and 
the trypsin-like serine proteases (leupeptin) and chymotrypsin-like 
serine proteases (TPCK) in the T. gondii-dependent degradation 
of BCL2-family members. Leupeptin (Sigma Aldrich, Milwaukee, 
WI, USA, L2023) was dissolved in sterile distilled water and used 
at a final concentration of 10 μg ml−1 leupeptin in α-MEM. TPCK 
(Sigma, Milwaukee, WI, USA, T4376) in DMSO was diluted in 
α-MEM to a final working concentration of 10 μM. The E64d 
stock (Sigma Aldrich, Milwaukee, WI, USA, E8640) was dissolved 
in 50% methanol and diluted into the medium to a concentration 
of 100 μM. In experiments using inhibitors dissolved with solvents 
other than water, control cells were treated with α-MEM containing 
an identical volume of the solvent as the inhibitor α-MEM.
densItometrIc analysIs of the Immunoblots and data 
analysIs
Normalized protein levels were determined using densitometric 
analysis. This was performed using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA) to calculate the integrated 
density of both the band of interest (BCL2, BAX, BAD, or BID) 
and the corresponding loading control band (calnexin). Multiple 
immunoblot exposures were scanned into digital files and opened 
using ImageJ software. The background was subtracted from the 
image using the subtract background function and the image was 
inverted. The membranes had been exposed to film for multiple 
lengths of time and the exposure judged to be in the linear range 
was quantitated. Normalized protein level values represent the 
integrated density value (IDV) of the band of interest divided by 
the integrated density of the loading control band (e.g., BCL2/cal-
nexin). Finally, the resulting values for multiple experiments were 
averaged and the SD was calculated. Given the variability of the 
data the following considerations went into the exclusion of specific 
experiments. (1) The presence in any lane of a given experiment 
of a protein of interest/calnexin ratio >2.5 was typically due to a 
problem with the loading control (data not shown) and was there-
fore excluded. (2) Immunoblots with a high uneven background 
cells by T. gondii results in the selective degradation of pro-apoptotic 
BCL2-family members (BAD, BAX) while the anti-apoptotic BCL2-
protein remained relatively unaffected (Carmen et al., 2006). With 
this study we investigate the contribution of NFκB, a key player 
in the parasite enforced blockade of apoptosis (Payne et al., 2003; 
Carmen and Sinai, 2007), as well as the roles of specific classes of 
proteolytic activities (Otlewski et al., 2005) on the selective parasite 
induced degradation. The results indicate that multiple activities 
target the specific proteins to ensure their stability. The data further 
suggest the differential stability profiles in response to infection 
may be due to both the direct impact of parasite activities as well 
the induction of host cell activities. In addition to increasing our 
understanding of the molecular basis for the T. gondii enforced 
block of apoptosis, additional insights into the biology of the BCL2-
family of proteins are revealed.
materIals and methods
cell and parasIte maIntenance
Wild type mouse embryonic fibroblasts [WT MEF (line WT-1)] 
and the NFκB p65−/− mouse embryonic fibroblast line RelA-2 
(Gapuzan et al., 2005), graciously provided by Dr. Alexander 
Hoffmann (University of California, San Diego), were main-
tained in α-minimal essential medium (α-MEM) supplemented 
with 100 units ml−1 penicillin, 100 μg ml−1 streptomycin, 7% heat-
inactivated fetal bovine serum and 2 mM l-glutamine (Gibco 
Invitrogen, Carlsbad, CA, USA). The RH strain of T. gondii with a 
deletion in the hypoxanthine-xanthine-guanine-phosphoribosyl-
transferase (HXGPRT) gene (Donald and Roos, 1998) was used in 
these experiments (NIH AIDS Research and Reference Program). 
Parasites were maintained by serial passage in Vero cells as described 
previously (Payne et al., 2003).
analysIs of the effect of T. gondii  InfectIon on bcl2, baX, bad, 
and bId levels
The effect of infection on the levels of BCL2, BAX, BAD, and BID 
was determined in WT MEF or p65−/− (RelA-2) MEF (Gapuzan 
et al., 2005) infected with increasing numbers of parasites [mul-
tiplicity of infection (MOI) = 0, 2, 4, 6, 8, or 10 tachyzoites per 
cell]. Cells were seeded into six-well dishes and incubated at 37°C 
for 8 h. Prior to infection, T. gondii tachyzoites were harvested, 
washed with PBS, and counted. The parasites were diluted in com-
plete α-MEM, added to the six-well dishes, and the dishes were 
returned to a 37°C incubator for 20 h. After this incubation, the 
cells were harvested, resuspended in 1.0% Triton x-100 in PBS and 
centrifuged at 10,000 rpm for 7 min to remove insoluble material. 
The total protein concentration of the resulting supernatant was 
determined using a BCA Protein Assay Kit (Pierce Biotechnology, 
Inc., Rockford, IL, USA) and equal amounts of total protein were 
resolved via SDS-PAGE on 12% gels and analyzed via immu-
noblot as described previously (Payne et al., 2003). Blocking of 
immunoblots was performed with 5% bovine serum albumin in 
phosphate buffered saline containing 0.2% Tween 20. The antibod-
ies used were: mouse monoclonal anti-BCL2 (1:500, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA, sc-7382), mouse mono-
clonal anti-BAX (1:500, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA, sc-7480), rabbit polyclonal anti-BAD (1:12,000, Stressgen 
Bioreagents, Ann Arbor, MI, USA, AAP-020), and rabbit polyclonal 
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Section “Materials and Methods.” Notably, in addition to defining 
the mean and SE we performed repeated measures ANOVA com-
paring the levels of significance for the infection level dependent 
loss of specific BCL2-family proteins. In addition, significant differ-
ences were recorded in pairwise comparisons relative to uninfected 
controls.
Consistent with previously published work we report that 
increasing T. gondii infection levels (MOI from 2 to 10) results in 
differential impacts on the anti-apoptotic BCL2-protein and the 
pro-apoptotic proteins BAX, BAD, and BID (Carmen et al., 2006). 
The BCL2-protein remains largely stable in the face of infection 
(Figure 1A). In compiling data from multiple independent experi-
ments this trends is validated with a small though statistically insig-
nificant dip at the highest MOI (Figure 1B). Overall the degradation 
of BCL2 across the entire infection range (MOI) was found not 
be significant (p-value 0.0899). In contrast the multi-domain pro-
apoptotic BAX is highly susceptible to infection-mediated degrada-
tion as evidenced in the representative gel (Figure 1A) and from 
the compiled quantitative data which shows a significant reduction 
in BAX steady state levels with an MOI of 2 and 4 (Figures 1A,B; 
p-value < 0.0001). The BH3-only proteins BAD and BID exhibit 
an intermediate phenotype being moderately sensitive (at MOI of 
6–8) to infection-mediated degradation (Figures 1A,B; p-values 
of 0.0265 and 0.0083 respectively).
host nfκb actIvIty alone Is not the basIs of the dIfferentIal 
stabIlIty In response to InfectIon
Our previous studies have established NFκB as an important medi-
ator of the parasite-blockade of apoptosis (Molestina et al., 2003; 
Payne et al., 2003). This relationship however is not universally 
applicable to all aspects of apoptosis as NFκB shows no involve-
ment in the infection-mediated block of JNK activation a key event 
in UV induced apoptosis (Carmen et al., 2008). The availability of 
RelA/p65−/− fibroblasts (Gapuzan et al., 2005) allows us to directly 
investigate the role of the intact NFκB cascade on the parasite medi-
ated degradation of BCL2-family proteins.
In the absence of NFκB activity we observe what appears to be 
increased sensitivity of BCL2 to infection-mediated degradation 
with some protein loss at an MOI of 6 (Figures 2A,B). However 
this difference was not seen to be statistically significant (Figure 2C, 
p-value 0.7071). Likewise, the apparent trend for the multi-domain 
member BAX was sustained relative to infection of WT MEF’s 
(Figures 2A–C). This trend was not found to be statistically sig-
nificant (p-value 0.1122). In contrast the BH3-only members BAD 
and BID exhibited some stabilization with appreciable degradation 
only at the highest MOI (Figures 2A–C). Overall the data indicate 
that the post transcriptional stability of BCL2-family members is 
not significantly regulated by NFκB dependent activities.
InhIbItIon of proteasomal degradatIon selectIvely Impacts 
the bh3-only famIly members
Proteasome mediated protein degradation is involved in the regu-
lated turnover of diverse cellular proteins (Hoff et al., 2004). Proteins 
are targeted for degradation by their ubiquitination (Hoff et al., 
2004). The drug MG132 is readily membrane permanent and irre-
versibly blocks the activity of the proteasome (Lee and Goldberg, 
1998). We reasoned that treatment of infected cells using MG132 
level impinging on bands of interest were also excluded. Using the 
criteria for exclusion a minimum of four independent experiments 
were recorded for a given condition. The specific number of experi-
ments employed in the statistical analysis is indicated in the figure 
legend for each sample.
statIstIcal analyses
The IDV values comprising the ratio of exposure level of the protein 
of interest relative to calnexin were analyzed using the GraphPad 
Prism software program. The data are presented in a graphical form 
as the mean for the specific sample with the error bars correspond-
ing to the SE of the mean. In addition, we performed One-way 
analysis of variance (ANOVA) tests using the Repeated Measures 
Test. The repeated measures test is ideal given the experimental 
design as matched subjects are used in each experimental replicate. 
Accordingly, the variance in the relative level of the specific protein 
is measured across the MOI range for the specific experimental 
parameter. Thus the significance of the trend across the MOI range 
can be established. The level of significance was set at a p-value 
of <0.05.
The repeated test ANOVA analyses for the effect of the inhibi-
tors used (Figures 3–6) are noted in Table 1. In addition to the 
analysis of the specific trends, the Dunnett test, whereby pairwise 
comparisons of significance (set at p < 0.05) are made for a given 
MOI relative to the uninfected control, was used. The MOI’s meet-
ing this criterion are marked with an asterisk in the figures.
 Finally, we established a representational scale based on the 
relative sensitivity of the protein to infection-mediated degrada-
tion. This scale follows the trend of the mean relative protein level 
pointing to specific trend whether or not it is statistically signifi-
cant at the established p < 0.05 for the given data set. Accordingly 
proteins exhibiting degradation at a MOI = 2 or 4 (+++) are 
highly sensitive, proteins for which the onset of degradation is at 
MOI – 6 to 8 are moderately sensitive (++) while those showing 
degradation at MOI = 10 are deemed marginally sensitive (+). 
Those proteins that fail to show any degradation based on the 
quantified results are insensitive to infection-mediated degrada-
tion (−; Table 1).
results
dIfferentIal sensItIvIty of bcl2-famIly members to InfectIon-
medIated degradatIon
We previously reported that T. gondii infection induces the selec-
tive loss of pro-apoptotic BCL2-family proteins in an infectious 
dose dependent manner (Carmen et al., 2006). In addition, stud-
ies on host transcriptional changes in response to infection fail to 
explain the specific loss of pro-apoptotic BCL2-family proteins 
(Molestina et al., 2003). In order to rigorously address the phe-
notype we reexamined the apparent selective degradation of pro-
apoptotic BCL2-proteins using the more quantitative approaches 
described in the material and method. In our analyses we examined 
the anti-apoptotic protein BCL2, the multi-domain pro-apoptotic 
member BAX, and two BH3-only pro-apoptotic proteins BAD and 
BID (Thomadaki and Scorilas, 2008). Analysis of this nature is 
subject to considerable variation from experiment to experiment. 
Applying a ratiometric approach addresses some of this variability. 
Specific criteria for the inclusion of data are  summarized in the 
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Figure 1 | The effect of Toxoplasma gondii infection on the steady state 
levels of the BCL2-family proteins in WT MeF. (A) Representative 
immunoblots detecting the levels of the anti-apoptotic BCL2, pro-apoptotic 
multi-domain member BAX and the BH3-only proteins BAD and BID in 
response to increasing infection (multiplicity of infection range 0 (uninfected) 
to 10). The signal for calnexin is used as a loading control. (B) Quantification of 
the relative levels of BCL2-family proteins relative to the corresponding signal 
for calnexin in response to infection at a given MOI. The multiplicity of infection 
for a given protein is denoted in the parenthesis following the name of the 
target protein. Using criteria outlined in the Section “Materials and Methods,” 
the following number of independent experiments were used to assemble the 
presented data: BCL 2–8 experiments, BAX-10 experiments, BAD-8 
experiments and BID-6 experiments. The error bars represent the SE of the 
mean (symbol). A single asterisk above an error bar signifies a significant data 
point relative to the uninfected control with a p-value <0.05 employing the 
Dunnett pairwise test. (C) Repeated measures ANOVA analysis relative to the 
uninfected control was performed. A p-value of 0.05 or higher were 
considered to be not significant (ns). Values of low significance (*0.01–0.05), 
moderate significance (**0.001–0.01), highly significant (***<0.001) 
were used.
Figure 2 | The effect of Toxoplasma gondii infection on the steady state 
levels of the BCL2-family proteins in NFκB knock out fibroblasts  
(p65−/− MeF). (A) Representative immunoblots detecting the levels of the 
anti-apoptotic BCL2, pro-apoptotic multi-domain member BAX and the BH3-only 
proteins BAD and BID in response to increasing infection [multiplicity of 
infection range 0 (uninfected) to 10]. The signal for calnexin is used as a loading 
control. (B) Quantification of the relative levels of BCL2-family proteins relative 
to the corresponding signal for calnexin in response to infection at a given MOI. 
The multiplicity of infection for a given protein is denoted in the parenthesis 
following the name of the target protein. Using criteria outlined in the Section 
“Materials and Methods,” the following number of independent experiments 
were used to assemble the presented data: BCL2–5 experiments, BAX-4 
experiments, BAD-4 experiments and BID-4 experiments. The error bars 
represent the SE of the mean (symbol). Specific data points with asterisk define 
a statistically significant difference (p < 0.05) in a pairwise test relative to the 
uninfected control. (C) Values for a repeated measures ANOVA across the MOI 
range for each protein indicates no significant overall change in NFκB deficient 
cells in response to infection.
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 markedly reduced in drug treated uninfected cells (MOI = 0). This 
would suggest that a proteasome-sensitive stabilizing activity is 
involved in the normal turnover of BID (Figures 3B,C). Such a fac-
tor could be akin to a protease inhibitor, whose expression, turnover 
or activity could be impacted.
Interestingly, while MG132 failed to have any effect on the 
stability of BCL2 and BAX in response to infection, the capacity 
to degrade BAD and BID by the infection-mediated component 
was effectively lost (Figure 3C). This is noted in the essentially 
flat profile of the curve for MG132 treated BAD and BID cells 
(Figure 3C). MG132 is known to be an inhibitor of NFκB due to 
as described in Figure 3A would establish a role for proteasome 
mediated turnover of the BCL2-family proteins in response to infec-
tion. Our reasoning was that in the presence of the inhibitor steady 
state levels of the proteins would increase if proteasome-mediated 
turnover was responsible for the degradation of the specific pro-
tein. On account of the inherent variability in such experiments we 
conducted repeated measure ANOVA across the MOI range for the 
treated samples and their matched controls (Table 1).
The levels of none of the BCL2-family proteins were 
enhanced (higher relative levels at MOI = 0) in non–infected 
cells (Figures 3B,C). However, the steady state level for BID was 
Figure 3 | effect of proteasome inhibition with Mg132 on the steady state 
levels of BCL2-family proteins in both uninfected (MOi = 0) and infected 
(MOi 2–10) cells. (A) Experimental strategy for the establishment of infection 
and treatment with the inhibitor. (B) Representative immunoblots detecting the 
levels of the indicated BCL2-family members in response to increasing infection. 
Levels of calnexin are used as a loading control. (C) Quantification of the levels of 
specific BCL2-proteins relative to calnexin in response to increasing infecting 
dose. Profiles for no-treatment (NT, DMSO) and treated (MG132) samples are 
indicated along with the MOI in parentheses. The mean relative level is indicated 
by the symbol with the error bards representing the SE of the mean. A single 
asterisk above an error bar signifies a significant data point relative to the 
uninfected control with a p-value <0.05 employing the Dunnett pairwise test. The 
data presented were derived four independent replicates for each BCL2-family 
member. ANOVA data from this experiment are compiled in Table 1.
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degradation of all of the BCL2-family proteins, except for BAX, 
was largely unaffected by E64d treatment as the general patterns 
for infection-mediated BCL2 member degradation was similar in 
treated and untreated samples (Figure 4). For all but BAX, the 
ANOVA values are similar when comparing untreated (NT) to the 
E64d treated samples. In the case of BAX however E64d resulted 
in a highly significant loss of variability at all the MOI’s examined 
(Figure 4B; Table 1).
InhIbItIon of “trypsIn-lIke” serIne proteases has dIfferentIal 
effects on bcl2-famIly members
Leupeptin is a broad spectrum membrane permeant inhibitor 
of trypsin-like serine protease activities (Kurinov and Harrison, 
1996). Treatment of uninfected cells (MOI = 0) with leupeptin 
using the strategy presented in Figure 3A resulted in no effect for 
BCL2, BAX, or BAD (Figure 5). In contrast the mean steady state 
level of the BH3-only protein BID was enhanced in the presence 
of leupeptin (Figure 5), although the error bars are pronounced. 
These data would suggest that normal turnover of BID is medi-
ated by a trypsin-like activity which, when inhibited, results in the 
accumulation of the protein in uninfected cells.
We examined the effect of leupeptin on the infection-mediated 
degradation of the BCL2-family proteins. While not affecting the 
levels in BCL2 in uninfected cells, levels of the protein trended in 
an upward direction with increasing infection (Figure 5). This 
upward trend, however, was not statistically significant based on 
ANOVA analysis (Table 1). There was no effect on the infection-
dependent degradation of BAX (Figure 5; Table 1). In contrast, 
in the presence of leupeptin the infection-mediated degradation 
of BAD was reduced, with the protein becoming marginally sensi-
tive to degradation (Figure 5; Table 1). Interestingly the marked 
the block in the degradation of the ubiquitinated Phospho-IκBα, 
the inhibitor of NFκB (Karin and Lin, 2002; Giuliano et al., 2003). 
It is therefore interesting that the pattern for infection-mediated 
degradation of BAD and BID follows a profile similar to that in 
infected RelA/p65−/− cells with the onset of degradation occur-
ring at the highest MOI (Figure 2). This suggests that an NFκB-
regulated proteolytic activity is involved in the parasite-directed 
degradation of BH3-only proteins. Conversely enhanced stabil-
ity of a protease inhibitor following proteasome inhibition could 
explain the absence of the infection-dependent degradation of 
these BH3 only proteins. The effects of MG132 on the parasite 
mediated degradation of BCL2-family proteins was subjected to 
ANOVA analysis. As reported in Table 1, MG132, resulted in the 
loss of infection-mediated degradation of BAD and BID with a 
similarly pronounced effect on BAX. BCL2 itself was unaffected 
when comparing the profiles for untreated and MG132 treated 
samples across the MOI range.
cysteIne proteases dIfferentIally Impact the pro-apoptotIc 
bcl2-famIly members
The membrane permeable cysteine protease inhibitor E64d 
(Hernandez and Roush, 2002; Lindvall, 2002) was used to establish 
the role of this class of proteolytic activities in stability of BCL2-
family member. Inhibitor treatment using a regimen identical to 
that above (Figure 3A) indicates that the inhibition of cysteine 
proteases has no significant effect on BCL2 levels and causes a 
small increase in the stability of BAX in the absence of infection 
(MOI = 0; Figures 4A,B). There was no effect on the inherent 
stability of BAD; however, E64d treatment resulted in a marked 
reduction in steady state BID levels. The effect on BID mirrors that 
seen for MG132 (Figure 3). Interestingly, the infection-mediated 
Table 1 | impact of proteasome and protease inhibition on the stability of BCL2-family proteins in uninfected cells and in response to infection.
inhibitors BCL2 BAX BAD BiD
PrOTeAsOMe
MG132 alone No effect No effect No effect Decreased stability
Infection + MG132 NT (+/−) MG132 (+/−) NT (+++) MG132 (+++) NT (++) MG132 (+/−) NT (+++) MG132 (+/−)
ANOVA 0.8123 0.9926 0.0037 0.1067 0.0894 0.8026 0.0020 0.9314
CysTeiNe PrOTeAses
E64d alone No effect Increased stability No effect Decreased stability
Infection + E64d NT (+/−) E64d (+/−) NT (+/−) E64d (+++) NT (+++) E64d (++) NT (+++) E64d (+++)
ANOVA 0.8395 0.5688 0.1914 0.0001 0.0074 0.0100 0.0244 0.0231
TryPsiN-LiKe
Leupeptin alone No effect Increased stability No effect Increased stability
Infection + Leu NT (+/−) LEU (−) NT (+++) LEU (+++) NT (++) LEU (+/−) NT (+++) LEU (+/−)
ANOVA 0.6567 0.3139 0.0016 0.0008 0.0283 0.6257 0.0110 0.3831
ChyMOTryPsiN-LiKe
TPCK alone No effect Increased stability Decreased stability Decreased stability
Infection + TPCK NT (+/−) TPCK (+/−) NT (+++) TPCK (+++) NT (++) TPCK (+/−) NT (+++) TPCK (+/−)
ANOVA 0.6773 0.3189 0.0122 0.0065 0.0157 0.3410 0.0059 0.3147
The sensitivity to degradation is classified using a scale correlating the multiplicity of infection (MOI) required for substantial loss of steady sate levels of the given 
protein. Accordingly, highly sensitivity to infection induced degradation (MOI of 2 or 4): +++, moderately sensitive to infection induced degradation (MOI of 6–8): 
++, marginally sensitive to infection induced degradation (MOI of 10: +, insensitive to infection induced degradation: −). Additionally values from repeated measures 
ANOVA are presented. p-Values <0.05 are considered significant. NT, no-treatment.
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“chymotrypsIn-lIke” serIne proteases dIfferentIally Impact 
pro-apoptotIc bcl2-famIly members
The chymotrypsin-like proteases can be inhibited by TPCK 
(Frydrych and Mlejnek, 2008). TPCK treatment of infected cells 
using the modality in Figure 3A indicates that BCL2 levels are 
not controlled by a chymotrypsin –like serine protease (Figure 6; 
Table 1). In contrast, treatment of uninfected cells (MOI = 0) with 
TPCK resulted in the accumulation of the multi-domain family 
member BAX (Figure 6; Table 1) but reduced levels of both the 
BH3-only proteins BAD and BAX (Figure 6). Furthermore, levels 
of BAD were fount to be quite variable. This differential effect on 
the pro-apoptotic BCL2-family suggests that chymotrypsin-like 
activities may degrade BAX directly. The reduced steady state  levels 
reduction in variability of BAD levels was seen only for this pro-
tein in the presence of leupeptin. This phenotype is exactly the 
opposite to what was observed for BID, where steady state levels 
were seen to become, highly variable on account of leupeptin. 
Furthermore, the effect of leupeptin in increasing the steady 
state levels of BID in uninfected cells, did have an impact on the 
infection-mediated turnover as that effect was blunted (ANOVA 
p-value 0.011 in untreated and 0.3831 in treated samples; Figure 5; 
Table 1). This indicates a distinct activity from that involved in 
the normal leupeptin-sensitive turnover of BID is present in the 
parasite infected cell. This could be either a host activity induced 
in the infected cell or a parasite derived activity secreted into the 
host cytoplasm.
Figure 4 | effect of cysteine protease inhibition with e64d on the steady 
state levels of BCL2-family proteins in both uninfected (MOi = 0) and 
infected cells (MOi 2–10). (A) Representative immunoblots detecting the levels 
of the indicated BCL2-family members in response to increasing infection. 
Levels of calnexin are used as a loading control. (B) Quantification of the levels 
of specific BCL2-proteins relative to calnexin in response to increasing infecting 
dose. Profiles for no-treatment (NT, untreated) and treated (E64) samples are 
indicated along with the MOI in parentheses. The mean relative level is indicated 
by the symbol with the error bards representing the SE of the mean. A single 
asterisk above an error bar signifies a significant data point relative to the 
uninfected control with a p-value <0.05 employing the Dunnett pairwise test. 
The data presented were derived from three independent replicates for each 
BCL2-family member. ANOVA data from this experiment are compiled 
in Table 1.
Frontiers in Microbiology | Cellular and Infection Microbiology  January 2011 | Volume 2 | Article 1 | 8
Carmen and Sinai T. gondii manipulation of BCL2-family proteins
 infection-mediated degradation of the BH3-only proteins involves 
serine protease activities (both trypsin- and chymotrypsin-like) 
that may be induced in response to the infection or be secreted 
directly by the parasite.
dIscussIon
The key triggering event in the induction of apoptosis along the 
intrinsic pathway is the release of cytochrome c from mitochondria 
resulting in the activation of the initiator and eventually executioner 
caspases (Pinkoski et al., 2006; Wang and Youle, 2009). The caspases 
systematically and irreversibly dismantle key activities ensuring the 
of both BH3 only proteins suggest an indirect effect where the 
inhibition of TPCK may result in the stabilization of a degradative 
activity with a distinct inhibitor profile.
Chymotrypsin-like serine protease activities do not appear to 
play a role in the infection-mediated turnover of BCL2 or BAX. 
However the activities associated with the infection-mediated 
degradation of the BH3-only proteins BAD and BID are inhib-
ited as evident from the slope of the curves in response to the 
increasing infection dose. This trend is validated by the ANOVA 
data indicating a marked loss of variability in levels of these pro-
teins due to infection (Table 1). Thus we can conclude that the 
Figure 5 | effect of trypsin-like serine protease inhibition with leupeptin 
on the steady state levels of BCL2-family proteins in both uninfected 
(MOi = 0) and infected cells (MOi 2–10). (A) Representative immunoblots 
detecting the levels of the indicated BCL2-family members in response to 
increasing infection. Levels of calnexin are used as a loading control. 
(B) Quantification of the levels of specific BCL2-proteins relative to calnexin 
in response to increasing infecting dose. Profiles for no-treatment (NT, 
untreated) and treated (Leu) samples are indicated along with the MOI in 
parentheses. The mean relative level is indicated by the symbol with the error 
bards representing the SE of the mean. A single asterisk above an error bar 
signifies a significant data point relative to the uninfected control with a 
p-value <0.05 employing the Dunnett pairwise test. The data presented were 
derived from four independent replicates for each BCL2, BAX, BID, and 
untreated BAD samples. Three independent experiments were used for the 
BAD immunoblots with leupeptin treatment. ANOVA data from this 
experiment are compiled in Table 1.
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et al., 2003). As a  countermeasure, pathogens have evolved elaborate 
 mechanism to disrupt the apoptotic response (Barry and Beaman, 
2006; Carmen and Sinai, 2007; Faherty and Maurelli, 2008; Galluzzi 
et al., 2008).
As an obligate intracellular parasite, T. gondii is critically depend-
ent on its ability to block apoptosis (Carmen and Sinai, 2007). This 
blockade is established at multiple levels involving the transmission 
of an apoptotic signal, the triggering of the apoptogenic response 
and finally its execution. Our studies have firmly established a 
vital role for the transcription factor NFκB in the establishment 
of the overall apoptotic stage (Molestina et al., 2003; Payne et al., 
2003; Molestina and Sinai, 2005a,b). However the role of NFκB-
mediated effects is not universal when examining how the parasite 
impacts specific components in the apoptotic process. Accordingly, 
progression to an apoptotic death. Given the finality of cell death, 
cytochrome c release is under tight regulation (Goldstein et al., 
2000; Gogvadze et al., 2006). The pro- and anti-apoptotic arms of 
the BCL2-family proteins govern the balance of activities ensur-
ing maintenance of cell viability or committing it to an apoptotic 
death (Scorrano and Korsmeyer, 2003; Brunelle and Letai, 2009). 
The BCL2-family is defined by the presence of the BH domains. 
The anti-apoptotic protein BCL2 possesses BH1, 2, 3, and 4 (Liston 
et al., 2003). Among the pro-apoptotic proteins BAX is a multi-
domain (BH1, 2, 3) protein (Lalier et al., 2007) while both BAD and 
BID possess only the BH3 domain (Marsden and Strasser, 2003). 
In multicellular organisms, apoptosis provides an effective defense 
mechanisms against pathogen attack by sacrificing an infected 
cell thus controlling the pathogens capacity to replicate(Hasnain 
Figure 6 | effect of chymotrypsin-like serine protease inhibition with 
TPCK on the steady state levels of BCL2-family proteins in both 
uninfected (MOi = 0) and infected cells (MOi 2–10). (A) Representative 
immunoblots detecting the levels of the indicated BCL2-family members in 
response to increasing infection. Levels of calnexin are used as a loading 
control. (B) Quantification of the levels of specific BCL2-proteins relative to 
calnexin in response to increasing infecting dose. Profiles for no-treatment (NT, 
untreated) and treated (TPCK) samples are indicated along with the MOI in 
parentheses. The mean relative level is indicated by the symbol with the error 
bards representing the SE of the mean. A single asterisk above an error bar 
signifies a significant data point relative to the uninfected control with a 
p-value <0.05 employing the Dunnett pairwise test. The data presented were 
derived from five independent replicates for BCL2, BAD, and BID. Five 
independent replicates were used for untreated BAX samples while four were 
included for the TPCK treated condition. ANOVA data from this experiment are 
compiled in Table 1.
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while the  inhibition of caspase activity is completely dependent on 
 NFκB-regulated components, the infection-mediated inhibition of 
JNK-kinases following UV irradiation is independent of it (Carmen 
et al., 2006, 2008) despite evidence for considerable crosstalk 
between the NFκB and JNK pathways (Papa et al., 2006; Wullaert 
et al., 2006). The complexity of the response is further evident 
in the differential response of BCL2-family proteins to infection 
as seen in multiple studies. As a whole, multiple studies demon-
strate that T. gondii infection shifts the balance of BCL2-proteins 
to favor an anti-apoptotic state (Goebel et al., 2001; Carmen et al., 
2006; Hippe et al., 2009a,b). This shift is evident from the selec-
tive degradation of pro-apoptotic BCL2-family proteins and the 
relative resistance to degradation of the anti-apoptotic members 
(Carmen et al., 2006). A pathogen mediated selective degradation 
of pro-apoptotic BCL2-family proteins has also been reported in 
Chlamydia infected cells (Zhong et al., 2001; Dong et al., 2005; Ying 
et al., 2005). The phenotype of infection-dependent degradation 
may be connected to the parasite strain as others, using an avirulent 
Type II isolate fail to observe this phenotype (Hippe et al., 2009b). 
In their study, they point out that in the absence of quantification 
in our prior work the degradation phenotype was not delineated 
(Hippe et al., 2009a). We chose to delve deeper into the potential 
mechanistic basis of this response by investigating the involvement 
of NFκB-mediated regulation as well as the selective inhibition 
of specific classes of proteases. We further examine the response 
quantitatively and confirm that the selective degradation of pro-
apoptotic BCL2-family members does in fact occur in response to 
Toxoplasma infection and present potential mechanisms for what 
is a complex phenotype.
The steady state level of any protein is governed by the balance 
of its inherent stability and its rate of synthesis. In pilot studies we 
blocked de novo protein synthesis using cycloheximide and moni-
tored the levels of BCL2-family proteins over time. These studies 
indicate a half life for BCL2 of around 6 h while that of BAD and 
BID was >8 h (data not shown). Interestingly, the multi-domain 
protein BAX exhibited a half life of around 2 h suggesting a rela-
tively high turnover (data not shown). This relative instability is 
reflected in the fact that BAX was found to be the most susceptible 
to infection-mediated degradation (Figure 1). Notably, the rates 
of degradation in response to infection for the BH3 only proteins 
BAD and BID exhibited moderate sensitivity (MOI 6–8; Figure 1). 
The anti-apoptotic BCL2-protein, which possesses BH1, 2, 3 and 
BH4 domains was inherently resistant to degradation (Figure 1) 
suggestive of a protective effect derived from the BH4 domain and/
or the increased expression as suggested from the transcriptional 
data (Molestina et al., 2003 and data not shown). Together the 
spectrum of responses is consistent with a complex network of 
activities at play.
The role of NFκB in the regulation of the apoptotic cascade is 
well documented (Karin and Lin, 2002). Transcriptional data on 
infected cells indicates that the anti-apoptotic proteins BCL2 and 
BFL1 are upregulated with BFL1 induction being strongly depend-
ent on NFκB (Molestina et al., 2003). In contrast infection fails to 
have any transcriptional consequence on the pro-apoptotic pro-
teins (Molestina et al., 2003 and data not shown). Interestingly, 
while BAX degradation was unchanged in RelA/p65−/− MEF’s the 
stability of BCL2 was compromised while that of the BH3 only 
proteins BAD and BID enhanced (Figure 2). Taken together the 
data suggest that NFκB differentially impact the different classes 
of BCL2-family of proteins during infection and that the trends 
correlate with a role for NFκB in establishing the anti-apoptotic 
state along the BCL2-family axis. It further suggests that multiple 
activities, potentially defined by the class of specific protein being 
targeted, governs its stability in the course of infection.
Protein turnover is governed by the activities of distinct degra-
dative mechanisms including the proteasome and a spectrum of 
proteases. We used well established membrane permeant inhibi-
tors of the proteasome (MG132), cysteine proteases (E64d), and 
serine proteases: including trypsin-like proteases (leupeptin) and 
chymotrypsin-like proteases (TPCK), to evaluate the impact on 
the stability of the BCL2-family proteins in response to infection. 
The lack of availability of membrane permeant inhibitors of other 
protease classes precluded analysis of their impact in intact cells. 
The results which are summarized in Table 1 confirm the com-
plexity of the networks governing turnover of these proteins in 
infected cells. The data in Table 1 represents a summary of the 
information presented in the figures dealing with the inhibition 
studies (Figures 3–6).
Our basic rationale was that the inhibition of a proteolytic activ-
ity would result in the accumulation of a target protein. In contrast, 
a reduction in the steady state level of a target protein following 
treatment with an inhibitor would suggest that the specific tar-
get may be an inhibitory, and therefore stabilizing activity. Thus 
loss of a protease inhibitor would increase steady state turnover, 
reducing the levels of the target protein. As evident in Table 1, 
the consequence of a specific inhibitor on the steady state level 
(MOI = 0, i.e., in the absence of infection) is to increase stability, 
increase turnover or have no effect. Notably the stability of BCL2 
was unaffected by any of the inhibitors used (Table 1). Furthermore, 
BAX, which was subject to the highest turnover, was stabilized 
by the inhibition of all the non-proteasome mediated degrada-
tion mechanisms. The results with the BH3-only proteins BAD 
and BID failed to follow an obvious pattern except in the case of 
chymotrypsin-like activities (inhibited by TPCK) where decreased 
inherent stability was observed (Table 1). All the other treatments 
failed to significantly impact steady state levels while clearly affect-
ing the inherent stability of BID (Table 1). The increased turnover 
of BID as a result of the inhibition of the proteasome, cysteine 
proteases, and chymotrypsin-like activities suggest the loss of a 
stabilizing activity. In contrast, the increased steady state levels of 
BID in the presence of leupeptin implicate trypsin-like activity in 
the normal turnover of BID (Figure 5). The effect of the proteasome 
and protease inhibitors on the infection-mediated stability of the 
BCL2-family proteins further establishes the relative insensitivity of 
BCL2 to infection-mediated degradation. To the contrary, a trend 
indicating an infection level dependent accumulation of BCL2 in 
the presence of leupeptin suggests a trypsin-like activity is specifi-
cally involved (Figure 5).
None of the inhibitors had any effect on the infection- mediated 
degradation of BAX (Table 1), despite the non-proteasome inhibi-
tors increasing the stability the protein in the absence of infec-
tion (Table 1). As a result, although the initial levels of BAX 
were typically higher, their degradation was evident at the lower 
multiplicities of infection (Figures 3–6). The greatest impact on 
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2004; Ying et al., 2005). Chlamydial CPAF additionally is inhibited 
by the proteasome inhibitor MG132 (Zhong et al., 2001; Byrne and 
Ojcius, 2004) an inhibition profile consistent with what we observe 
for T. gondii infection-mediated degradation specifically of BH3–
only proteins (Table 1). The availability of the T. gondii genome 
(www.toxodb.org) allows for the identification of potential CPAF-
homologs in this parasite that shares several features regarding the 
establishment of its intracellular niche with Chlamydiae (Sinai and 
Joiner, 1997). Of note the T. gondii genome encodes several secreted 
proteases and serpins which have been shown to be secreted into the 
parasitophorous vacuole but not into the host cell (Ahn et al., 2001; 
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A growing body of work reveals that the efficient targeting of 
cellular components by parasite effectors directly influences cel-
lular functions (Boyle and Radke, 2009). Our work with the PVM-
localized I κB kinase activity (Molestina and Sinai, 2005a,b), the 
work with the ROP-family kinases (reviewed in Peixoto et al., 2010) 
and a rhoptry derived phosphatase (Gilbert et al., 2007) delivered 
to the host nucleus all point to a highly refined system for host 
manipulation. Notably, among the proteins found in the rhoptry 
proteome are predicted proteases and peptidases (Bradley et al., 
2005) which could be delivered to the host cell like the ROP kinases. 
This study presents potential targets that are directly linked into the 
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reveals a new weapon in the arms race that defines the pathogen 
host interaction.
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infection- mediated stability was seen with the BH3-only proteins 
BAD and BID (Table 1). Judging from the slope of the curves, 
the inhibition of the proteasome effectively blocked the parasite 
mediated degradation in response to infection level (Figure 3C). 
This general trend is followed for leupeptin treatment (trypsin-like 
activities) where for BID the apparent decreases of the mean inten-
sity are neutralized by the significant SE (Figure 5B). This pattern 
repeats for both BAD and BID following TPCK (chymotrypsin-like 
activities) treatment (Figure 6B). The cysteine protease inhibitor 
E64d had a minor effect in stabilizing BAD requiring a higher infec-
tion dose to observe degradation (Figure 4).
A central question and unresolved question presented by this 
work is that of the source of the specific proteolytic and/or protective 
activities involved. What is clear is that multiple activities broadly 
focused on the class of the BCL2-family protein are involved. In 
the case of the relative stability of BCL2 in response to infection the 
data suggest a role for a “protective” activity that is at least partially 
regulated by NFκB. This suggests an indirect mechanism where 
the parasite is modulating host gene expression to sustain BCL2 
levels by the combined action of increased transcription (Molestina 
et al., 2003) and the potential induction of a protective activity. In 
this regard the identification of an NFκB induced serpin (serine 
protease inhibitor) that targets the serine protease family activities 
are intriguing (Dechend et al., 1999; Mutoh et al., 2008; Jerczynska 
and Pawlowska, 2009). The observation that leupeptin completely 
abolishes infection-dependent BCL2 degradation at the highest 
MOI is consistent with this conclusion (Figure 4).
Multiple proteolytic activities are involved in the degradation of 
the pro-apoptotic BCL2-proteins. The insensitivity of BAX degra-
dation in response to any of the inhibitors used suggests the involve-
ment of a distinct activity. Infection could induce the activity (by 
activation of a protease or elimination of an inhibitor) in the host 
cell or be the consequence of a secreted parasite protease.
In the case of the BH3 only proteins BAD and BID the capac-
ity for infection-mediated degradation is dampened or lost by the 
inhibition of the proteasome (Figure 3) as well as both trypsin- 
and chymotrypsin-like activities (Figures 5 and 6). The loss of 
degradation following proteasome inhibition implicates a ubiqui-
tin mediated turnover in the parasite induced degradation. This 
would suggest a mechanism that is indirectly impacted by parasite 
infection. In contrast, the effects of leupeptin and TPCK could be 
explained by the activation of a host protease, or loss of an inhibitory 
activity. Both trypsin and chymotrypsin are serine proteases and are 
therefore potentially inhibitable by the serpin class of endogenous 
serine protease inhibitors (Law et al., 2006). In addition the delivery 
of a specific parasite protease into the host cytoplasm cannot be 
ruled out. Such an activity has been described for the intravacuolar 
bacteria of the Chlamydia species which release CPAF (Chlamydia 
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